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Abstract: 
Background-Tai Chi Chuan (TCC) is an integrative medicine mind-body practice with a physical 
activity component that has positive effects on aerobic capacity, muscular strength, and quality 
of life among cancer survivors, similar to the effects elicited by other modes of moderate 
intensity exercise. Inflammatory cytokines, and insulin and insulin-related signaling molecules 
may contribute to weight gain and affect cancer recurrence rates and survival; exercise can curb 
cancer- and treatment-related weight gain, increase survival, and reduce levels of insulin and 
inflammatory cytokines. Despite knowing the beneficial effects of conventional exercise 
interventions on these mediators, little is known about the physiologic effects of TCC, a mind-
body practice with a physical activity component, on these pathways in breast cancer survivors. 
Methods-We assessed the effects of a 12-week, moderately intense, TCC intervention (n=9) 
compared to a non-physical activity control (n=10) consisting of psychosocial support therapy 
(PST) on levels of insulin, IGF-1, IGFBP-1, IGFBP-3 and cytokines IL-6, IL-2, and IFN-γ in 
breast cancer survivors. 
Results-Levels of insulin are significantly different in TCC and PST groups; levels remained 
stable in the TCC group, but increased in the PST control group (p=0.099). Bivariate analysis 
revealed novel and significant correlations (all r >0.45, all p≤0.05) of both decreased fat mass 
and increased fat-free mass with increased IL-6 and decreased IL-2 levels. 
Conclusions-This pilot study shows that TCC may be associated with maintenance of insulin 
levels and changes in cytokine levels that may be important for maintenance of lean body mass 
in breast cancer survivors. 
 
Article: 
INTRODUCTION 
Following the diagnosis of breast cancer, many women gain weight. Several studies have shown 
that the mean weight gain during the first year after diagnosis is 2.5 to 6.2 kg (range from 1.0 to 
greater than 11 kg) (1–4). The lowest gains are observed in those receiving local radiation 
therapy or adjuvant hormonal therapies (e.g. tamoxifen) alone. Highest gains appear in those 
receiving adjuvant chemotherapy alone or combined with hormonal therapies. In all cases, 
weight gain is persistent and still increasing 5 years after treatment (1–4). These levels of weight 
gain are greater than the weight gain experienced during normal aging and primarily represent an 
increase in fat mass and a loss of lean mass (fat-free mass), often referred to as sarcopenic 
obesity (5). While advances in oncology have dramatically increased survival for women with 
early-stage breast cancer, weight gain following diagnosis appears to negatively affect quality of 
life and recurrence rate (6). Additionally, weight gain post-diagnosis is associated with increases 
in all-cause mortality, breast cancer-specific mortality, and cardiovascular-related mortality; each 
5-kg increase in weight post-diagnosis increases mortality by 10–12% (7). 
 
Insulin and cytokine pathways may be key mediators of weight gain, recurrence, and survival for 
breast cancer survivors. Elevated fasting levels of insulin are associated with a 2-fold increased 
risk of breast cancer recurrence and a 3-fold decrease in survival (8). Indeed, insulin-related 
pathways involving insulin and insulin-like growth factors (IGFs) are associated with increased 
cell growth and proliferation (9), providing an explanation for the link between elevated insulin 
levels and tumor growth. Multiple pro-inflammatory signaling pathways involving cytokines 
have been implicated in cancer development, progression, and recurrence. These cytokines can 
alter proliferation, lead to malignant transformation, and promote metastasis (10). 
 
Exercise interventions for breast cancer survivors have positive effects on survival (11–13), 
quality of life (14), and weight (15), and preliminary evidence suggests that exercise may also 
reduce the risk of cancer recurrence. Accumulating evidence suggests that exercise may elicit 
these beneficial effects by minimizing levels of circulating insulin and inflammatory molecules, 
thus providing positive effects on weight, recurrence, and survival. Regular exercise (both 
aerobic and strength training) can lower circulating insulin levels, reduce insulin resistance, and 
reduce weight gain (16, 17). Several recent randomized controlled trials using moderately intense 
exercise interventions have investigated the effects of exercise on possible insulin-related 
predictors of recurrence and prognosis in breast cancer survivors (15, 18–22). For example, Irwin 
et al. found statistically significant decreases in fasting insulin, IGF-1, and IGFBP-3 in 
postmenopausal women who followed a moderately intense walking-based intervention of 5 
days/week for 6 months compared to non-exercisers (21). The 12-month intervention study by 
McTiernan et al. in postmenopausal breast cancer survivors showed that both exercising and 
stretching produced small reductions in IGF-1 and IGFBP-3; however, there were no significant 
differences in mean IGF-1 and IGFBP3 levels between the group that exercised and the group 
that stretched (20). Reductions in insulin are also associated with reductions in hip and waist 
circumference as shown in a mixed aerobic and strength training study by Ligibel et al., 
suggesting that decreased insulin levels may be associated with reductions in abdominal 
adiposity, which is strongly predictive of cardiovascular risk and risk of diabetes, in overweight 
survivors (15). 
 
Numerous studies in healthy individuals have revealed that exercise can reduce chronic 
inflammation by inducing anti-inflammatory effects (23). On a molecular level, during exercise, 
IL-6 is rapidly produced by contracting skeletal muscle fibers (24) and acts as a myokine with 
anti-inflammatory effects to inhibit pro-inflammatory cytokine expression (25). Exercise can 
also reduce adiposity by IL-6-mediated lipolysis and by diminishing levels of circulating and 
adipose-derived cytokines (e.g. TNF-α, IL-1β) in adults (26–28). 
 
These studies indicate that conventional exercise programs may represent a beneficial 
intervention for reducing fat mass, improving lean mass and altering insulin, insulin-related 
molecules, and inflammation to reduce recurrence risk in breast cancer survivors. However, 
whether integrative medicine approaches with a physical activity component, such as Tai Chi 
Chuan (TCC), may have the same beneficial effects on cancer patients and survivors remains 
unknown. 
 
TCC is a traditional Chinese martial art that combines slow, fluid, weight-bearing physical 
movements with deep, controlled breathing exercises and relaxation techniques. Many cancer 
patients and survivors are trying integrative medicine approaches, such as TCC, as a way of 
reducing side effects of treatment such as weight gain (29, 30). TCC, which may result in an 
energy expenditure equivalent to that of brisk walking, improves aerobic capacity, flexibility, 
strength, mood and quality of life in breast cancer survivors (31–33). Whether TCC, which has 
both a meditative and a physical activity component, can produce similar physiologic effects in 
breast cancer patients and survivors as traditional exercise programs is unknown. In a previous 
randomized controlled trial conducted by our research group, breast cancer survivors used a 15-
move yang-style TCC as a form of integrative medicine to control side effects from cancer 
treatments. We found that TCC significantly improved functional capacity, self-esteem, bone 
health and quality of life (32–35) and led to reduced fat mass compared to the non-exercising 
group, although this difference in fat mass was not statistically significant (34). 
 
Little is known about the mechanisms linking exercise and weight gain in breast cancer 
survivors. Moreover, we do not know whether TCC, an integrative medicine intervention with a 
meditative and a physical activity component, elicits similar physiologic responses as traditional 
exercise programs already investigated on breast cancer survivors. Because hormone (e.g. 
insulin) and exercise-mediated anti-inflammatory mechanisms (e.g. IL-6) are thought to be the 
most plausible explanation for the protective effects of exercise on weight gain and recurrence, 
we investigated the physiologic effects of TCC on insulin and cytokine levels. Additionally, 
interventions with meditative components are thought to have anti-inflammatory effects (36). 
Specifically, the current post-hoc pilot study was designed to identify molecules that may be 
altered by TCC and to identify novel correlative relationships between insulin and insulin-related 
molecules, cytokines, and fat and fat-free mass. Based upon the effects of traditional exercise in 
breast cancer survivors and the anti-inflammatory properties of exercise, we developed a model 
to explain plausible effects of physical activity interventions, such as TCC, on insulin, insulin-
related proteins, and cytokines) in breast cancer survivors (Figure 1). We hypothesized that TCC, 
like more traditional exercise interventions, would reduce insulin levels. We also hypothesized 
TCC would alter cytokine levels that may be linked with the reduction in fat mass and increase 
in fat-free mass induced by the TCC. 
 
  
Figure 1: Proposed model of the effects of a physical activity intervention on insulin, insulin-
signaling molecules and cytokines 
 
 
We hypothesize that IL-6 may contribute to inflammation-mediated cellular proliferation and ultimately tumor growth and increased recurrence 
risk in an environment of no physical activity (A). However, in the presence of an intervention with a physical activity and meditative component 
(e.g. TCC), increased levels of skeletal-muscle-derived IL-6 act in an anti-inflammatory manner and induce lipolysis leading to maintenance of a 
healthy weight and reduced risk of recurrence (B). 
 
 
 
PARTICIPANTS AND METHODS 
Participants 
The detailed methods of the original study assessing the effects of TCC on health-related quality 
of life, self-esteem, and functional capacity in breast cancer survivors have been previously 
described by Mustian and colleagues (32–34). Approval from the Institutional Review Board 
(IRB) was obtained prior to acquiring written consent and enrolling participants. Potential 
participants were required to meet the following criteria for inclusion in this study: (1) female; 
(2) primary diagnosis of breast cancer stages 0-IIIb; (3) treatment completed more than 1 month 
prior but less than 30 months prior; (4) no drainage tubes or catheters; (5) not taking part in 
moderate or vigorous physical activity more than once a week; (6) physician’s permission for 
aerobic fitness testing and exercise; (7) physically able to participate in an physical activity 
regimen; and (8) no clinical diagnosis of any mental disorder, as defined by the use of 
psychotropic drugs and self-report (32). 
 
Design and Procedures 
Participants were randomly assigned to either the TCC group or a psychosocial therapy (PST) 
control group for a period of 12 weeks. Both groups met for 60 minutes three times a week in 
separate classrooms in the same building at the same time of day for the duration of the trial. 
Randomization was achieved by the flipping of a coin, and group assignment was concealed 
from participants until the completion of all baseline assessments. All baseline assessments were 
completed two days prior to the start of the intervention. Adherence and compliance in the trial 
were monitored through attendance records and personal records kept by each participant. The 
PST group sessions, facilitated by a trained counselor and exercise psychology graduate student, 
placed special emphasis on behavioral coping strategies, peer support, and group cohesion. 
Participants in the PST and TCC arms were instructed not to change their pattern of physical 
activity in any manner for the duration of the study. 
 
The TCC group was led by an American College of Sports Medicine (ACSM) certified Health 
and Fitness Instructor. The instructor was extensively trained in Yang-style TCC and had more 
than six years of teaching experience. Each session consisted of a 10-minute warm-up, followed 
by a 40-minute session in which the participants learned and performed a 15-move short form of 
Yang-style TCC. The 15 moves used in this intervention comprise the first 15 moves of the 
traditional 104-move, long-form Yang-style TCC. In the final 10 minutes, participants were 
instructed to perform structured breathing, imagery, and meditation. 
 
All participants completed bioelectrical impedance tests to assess body composition at baseline 
and at twelve weeks. Fasting blood draws for each patient were also taken at these time-points. 
No formal assignments were given to participants to perform at home, but they were encouraged 
to practice the TCC and behavioral coping strategies they learned during the intervention. 
 
MEASURES 
Demographics and Medical Information 
Demographic and clinical information (i.e. participant’s age, weight, stage of disease, surgery 
type, and treatment regimens) were obtained from the patient or her medical record at the time of 
entry into the trial. In addition, body mass index (BMI, kg/m2) was calculated for each 
participant. 
 
Measurements of Insulin, Insulin-Related Molecules and Cytokines 
Fasting-state blood samples were collected at both pre- and post-intervention time-points 
(N=19). The blood samples were allowed to clot for ≥ 30 minutes, then centrifuged, and serum 
collected. Serum samples were then aliquotted and stored at −80°C until used for ELISA. Serum 
samples were shipped to a central reference laboratory and tested simultaneously to eliminate 
inter-assay variation. Serum concentrations of insulin were measured by radioimmunoassay 
(RIA) assay with commercial kits from Diagnostic Systems Laboratories, Inc. (Webster, TX, 
USA), and IGF-I, IGFBP-1, and IGFBP-3 were measured by immunoradiometric assay with 
commercial kits from Diagnostic Systems Laboratories, Inc. (Webster, TX, USA). Serum 
cytokines (IL-2, IL-6, and IFN-γ) were measured by OPT-EIA ELISA kits from BD Biosciences. 
 
Body Composition 
Body composition was assessed using bioelectrical impedance analysis (BIA, Quantum-II 
Desktop with a real-time resolution of 0.1 ohm) at both pre- and post-intervention as described in 
detail previously [10]. Patients were instructed to prepare for BIA by fasting 4 hours, not 
participating in physical activity for 12 hours, abstaining from alcohol and diuretics (unless 
prescribed) for 48 hours but remaining well hydrated. BIA measures opposition to the flow of an 
electric current through body tissues which is used to calculate total body water and fat-free 
mass. The resistance to flow is inversely related to both fat-free mass and total body water. Total 
body electrical conductivity and body composition determined by densiometry, such as 
hydrostatic weighing, are highly correlated (37). 
 
Statistical Analysis 
Data analyses were conducted using SPSS version 16.0 software. Descriptive statistics for the 
participants’ demographics and baseline values were calculated; percentages were calculated for 
categorical variables and means and standard deviations for continuous variables. Independent 
sample t tests were performed on all baseline characteristics. Means and standard deviations 
were calculated for all study outcome variables at pre-intervention and post-intervention and for 
change from pre- to post-intervention. Analyses of covariance (ANCOVA) with baseline values 
as a covariate were used to compare differences between groups at post-intervention in insulin, 
IGF-1, IGFBP-1, IGFBP-3, IL-2, IL-6 and IFN-γ. Pearson correlations were calculated to assess 
the association between changes in insulin, IGF-1, IGFBPs, serum cytokines, fitness outcomes, 
and body composition. All biomarker values are within assay range and are included in the 
analyses. Since this is a pilot study with a small sample size, two-sided p values of ≤ 0.10 were 
considered statistically significant in all cases. Preliminary effect sizes were determined using 
pre- and post-intervention means and standard deviations to calculate within-group Cohen’s d 
values. 
 
RESULTS 
Thirty-one breast cancer survivors agreed to participate; 21 participants successfully completed 
the trial. Reasons for withdrawal were previously reported in our original study and included: not 
liking their treatment group, work, family, and too many side effects following treatment. 
Additionally, those in the TCC group had a 72% exercise attendance rate and those in the PST 
group had a 67% attendance rate. Compliance at each attended session was 100% in both groups 
(32, 34). Nineteen participants agreed to give blood samples and are included in these analyses. 
Adequate amounts of serum were available for measurement of insulin, IGF-I, and IGFBPs in all 
subjects and cytokines in most subjects. Table 1 describes the baseline characteristics of these 
study participants. All participants were female and Caucasian with a mean age of 53 years 
(range from 43 to 78 years). No significant differences were noted between the groups in any of 
the baseline variables assessed (Table 1). Additionally, no significant group differences (p>0.10) 
were observed for any serum biological marker assessed at baseline except IFN-γ (p=0.086). 
 
Table 1: Baseline characteristics for TCC and PST randomized groups 
Characteristic TCC (n=9) PST (n=10) P-value 
Age (years) 54.33 (10.64) 52.70 (6.67) .0690 
Surgery   0.868 
Lumpectomy 55.60% 60.00%  
Unilateral Mastectomy 33.30% 30.00%  
Bilateral Mastectomy 11.10% 10.00%  
Radiation   0.387 
Yes 100%* 90.00%  
No 0%* 10.00%  
Chemotherapy   0.123 
Yes 66.70% 30.00%  
No 33.30% 70.00%  
Weight (Kg) 66.67 (14.87) 66.66 (9.84) 0.999 
Fat Mass (Kg) 27.36 (8.52) 27.88 (6.38) 0.665 
Fat Free Mass (Kg) 40.19 (6.67) 38.74 (5.34) 0.588 
BMI (Kg/m2) 24.89 (5.78) 24.97 (4.39) 0.971 
 
 
Values are represented as Means (Std. Dev.) or Frequencies 
*missing 1 value 
 
We previously reported the positive effects, although not significant, of TCC on BMI, weight, 
and fat mass in the 21 study participants who completed the original trial (34). We observed 
similar effects in the 19 individuals included in this analysis as in our previously reported results. 
Table 2 shows pre-intervention means, post-intervention means, and changes in weight, BMI, fat 
mass, and fat-free mass in TCC and PST groups. BMI in the TCC group decreased (Cohen’s d = 
−0.07), while BMI in the PST group increased (Cohen’s d = 0.06). Using ANCOVA, adjusting 
for baseline, BMI was significantly different between groups at post-intervention (p <0.10). No 
other significant differences were observed. Weight and fat mass decreased in the TCC group 
(Cohen’s d = −0.02 and −0.02, respectively) but increased in the PST group (Cohen’s d = 0.05 
and 0.04 respectively). Fat-free mass slightly decreased in the TCC group (Cohen’s d = −0.004) 
and increased in the PST group (Cohen’s d = 0.06). 
 
Table 2: Pre-intervention, post-intervention, and change score means for body composition 
measures in TCC and PST Groups 
Variable  Group Pre-Intervention Post-Intervention Change 
Weight (Kg)  TCC (9) 66.67 (14.85) 66.37 (14.68) -0.30 (1.86) 
  PST (10) 66.66 (9.85) 67.26 (10.33) 0.60 (1.43) 
BMI (Kg/m2)*  TCC (9) 24.89 (5.78) 24.47 (5.49) -0.42 (0.75) 
  PST (10) 24.97 (4.39) 25.26 (4.77) 0.29 (0.61) 
Fat Mass  TCC (9) 26.29 (9.26) 26.13 (8.15) -0.16 (2.91) 
  PST (10) 27.88 (6.38) 28.16 (6.25) 0.28 (1.57) 
Fat Free Mass  TCC (9) 40.27 (6.69) 40.24 (7.56) -0.03 (3.05) 
  PST (10) 38.74 (5.33) 39.1 (5.51) 0.36 (1.36) 
*p < 0.10, representing between-group effect at post-intervention controlling for pre-intervention baseline value 
 
 
Pre-intervention means, post-intervention means and mean changes in biomarkers insulin, 
insulin-related proteins, and cytokines were recorded (Table 3 and Figure 2). The significance of 
the differences between groups (main effect) at post-intervention was assessed with ANCOVA, 
incorporating baseline values as a covariate. There was a significant main effect for insulin 
(p=0.099); insulin levels remained relatively stable in the TCC group (mean change = 1.41; 
Cohen’s d = 0.20) but increased in the PST group (mean change = 15.02; Cohen’s d = 0.66;). 
The 15.02 increase represented a 1.80-fold increase in the PST group compared to a 1.12-fold 
increase in the TCC group. IGF-1 decreased in both groups; however, the decrease was greater in 
the TCC group (mean change = −27.32; Cohen’s d = −0.80) than in the PST group (mean change 
= −16.64; Cohen’s d = −0.23; p = 0.495 for the main effect). IGFBP-1 increased in both TCC 
(mean change = 3.76; Cohen’s d = 0.10) and PST groups (mean change = 9.12; Cohen’s d = 
0.20; p = 0.749 for the main effect). IGFBP-3 increased in the TCC group (mean change = 0.89; 
Cohen’s d = 0.13) but decreased in the PST group (mean change = −0.70; Cohen’s d = −0.05;, p 
= 0.299 for the main effect). 
 
The cytokine/myokine IL-6 increased in the TCC group (mean change = 2.00; Cohen’s d = 0.35) 
but decreased slightly in the PST group (mean change = −0.02; Cohen’s d = 0.01; p = 0.297 for 
the main effect). Both pro-inflammatory cytokines IL-2 (mean change = 4.59; Cohen’s d = 0.46) 
and IFN-γ increased in the PST group (mean change = 2.32; Cohen’s d = 0.19) but decreased in 
the TCC group (mean change = −8.82; Cohen’s d = −0.54 and −0.17; Cohen’s d = −0.08 
respectively), although the main effect was not significant for either IL-2 (p = 0.369) or IFN-γ (p 
= 0.831). 
 
Table 3: Pre-intervention, post-intervention, and change score means for biomarker levels in 
TCC and PST Groups 
Variable#  Group (n) Pre-Intervention Post-Intervention Change 
Insulin  TCC (9) 15.34 (5.36) 16.75 (7.99)* 1.41 (7.05) 
  PST (10) 15.83 (9.10) 30.85 (29.86) 15.02 (23.62) 
IGF-1  TCC (9) 156.81 (19.58) 129.49 (43.83) -27.32 (45.07) 
  PST (10) 111.76 (82.64) 95.12 (58.65) -16.64 (66.5) 
IGFBP-1  TCC (9) 72.64 (25.64) 76.40 (42.76) 3.76 (27.32) 
  PST (10) 92.22 (39.02) 101.34 (50.01) 9.12 (36.44) 
IGFBP-3  TCC (9) 39.22 (6.26) 40.11 (7.29) 0.89 (3.12) 
  PST (10) 40.81 (13.55) 40.11 (15.13) -0.700 (3.77) 
IL-6  TCC (9) 2.63 (3.96) 4.63 (6.97) 2.00 (5.53) 
  PST (10) 2.44 (1.79) 2.42 (1.74) -0.02 (1.51) 
IL-2  TCC (9) 12.48 (22.15) 3.66 (5.83) -8.82 (23.41) 
  PST (9) 3.73 (4.96) 8.32 (13.22) 4.59 (12.64) 
IFN-y  TCC (7) 1.34 (2.42)+ 1.17 (1.78) -0.17 (3.56) 
  PST (9) 7.79 (9.70) 10.21 (15.55) 2.42 (6.45) 
Values are represented as Means (Std. Dev.) 
#Insulin Units = μIU/mL, IGF-1, IGFBP-1 and IGFBP-3 Units = ng/mL, IL-6, IL-2 and IFN-γ Units = pg/mL 
*p ≤ 0.10, representing between-group effect at post-intervention controlling for pre-intervention baseline value 
+p ≤ 0.10, representing the significant between-group difference at baselines 
 
Figure2: 
Figure 2A: Changes in mean insulin and insulin related protein concentrations in TCC and PST 
groups 
 
 
Figure 2B: Changes in mean cytokines concentrations in TCC and PST groups 
 
In order to investigate possible linkages between fat mass, fat-free mass, insulin and insulin-
related proteins, and cytokines, we performed correlations on all available subjects. These 
correlation analyses were performed for hypothesis-generating purposes to identify potential 
targets that may be investigated in larger studies of TCC in breast cancer survivors. We were 
interested in identifying novel patterns among changes (between pre-intervention and post-
intervention means) for insulin and insulin-related proteins, cytokines and body composition. 
 
We found that changes in IGF-1 were negatively correlated with changes in IGFBP-1 (r=−0.694, 
p = 0.001); as IGF-1 decreased, IGFBP-1 increased. Additionally, we found changes in IGF-1 
were positively correlated with changes in IFN-γ (r = 0.562, p = 0.024); as IGF-1 increased, IFN-
γ increased. Changes in IFN-γ were positively correlated with changes in insulin (r = 0.488, p = 
0.055); as insulin decreased, IFN-γ also decreased. These data are summarized in Figure 3A. 
Additionally, we found that changes in fat-free mass were positively correlated with changes in 
IL-6 (r = 0.474, p = 0.040) and negatively correlated with changes in IL-2 (r = −0.491, p = 
0.038). As fat-free mass increased, IL-6 also increased but IL-2 decreased. Further supporting 
this result, we found that changes in fat mass negatively correlated with changes in IL-6 (r = 
−0.505, p = 0.028) and positively correlated with changes in IL-2 (r = 0.552, p = 0.018). As fat 
mass decreased, IL-2 also decreased but IL-6 increased (Figure 4A). 
 
Figure 3: Relationships between changes in IGF-1, IGFBP-1, IFN-gamma and insulin 
 
 
Figure 4: Relationship between changes in cytokines IL-6 and IL-2 and fat mass and fat-free 
mass 
 
 
We also assessed correlations by group to determine if differential patterns existed between 
intervention groups (Figures 3B, ,4B).4B). In both TCC and PST groups, changes in IGF-1 and 
changes in IGFBP-1 were negatively correlated (r = −0.739, p = 0.023 for TCC and r = −0.696, p 
= 0.025 for PST). The correlations for changes in IL-6, IL-2, fat mass and fat-free mass were 
higher for subjects in the TCC group than for those in the PST group (Figure 4B) suggesting that 
associations between the changes in these variables may result from the TCC intervention. 
 
DISCUSSION 
The goal of this study was to identify differential changes in biological marker profiles for 
insulin and cytokines in subjects who were randomized to a integrative medicine TCC 
intervention compared to a PST control, and to identify novel correlative relationships between 
insulin and insulin-related molecules, cytokines, and fat and fat-free mass. Of the insulin and 
insulin-related proteins and cytokines assessed for group differences at post-intervention (Table 
2), only insulin showed a change that was significant. Levels were stable and within normal 
range in the TCC group but almost doubled in the PST group over the 12-week intervention 
period to a level that would be considered high. The increase in insulin in the non-exercising 
(PST) group and the stabilized levels of insulin observed in the TCC group in our study are 
consistent with reports from others who prospectively measured insulin levels in breast cancer 
survivors undergoing an exercise intervention (21). We hypothesize that the increases in insulin 
in the PST group may be related to increases in weight and BMI observed in that group but not 
in the TCC group; however, further study would be needed to assess this. 
 
Because the TCC intervention led to stable levels of insulin over the 12-week period, this mind-
body intervention with a physical activity component may represent an effective intervention to 
maintain stable insulin levels in breast cancer survivors, much like conventional exercise 
programs. Maintenance of stable insulin levels appears to be very important in view of recent 
research showing that increased insulin levels are associated with increased recurrence risk and 
reduced survival in breast cancer survivors (8). 
 
This study revealed novel patterns in the relationships between changes in IL-6, IL-2, fat mass 
and fat-free mass, particularly those observed in the TCC group. We believe the positive 
correlation of changes in IL-6 and fat-free mass and inverse correlation of changes in IL-6 with 
fat mass, associations that are observed most strongly in the TCC group, might be indicative of 
physical activity-mediated changes in cytokines that are beneficial for maintenance of a healthy 
body weight in breast cancer survivors. 
 
IL-6 is a pleiotropic molecule that has both pro- and anti-inflammatory effects that may be 
related to the cellular source of production. In clinical studies, higher circulating levels of IL-6 
have been identified in those diagnosed with breast cancer than in healthy individuals (38). IL-6 
secreted from adipose tissue has been implicated in promoting invasion of breast cancer cells 
(39), and in a chronic inflammatory setting, IL-6 may be secreted by T-cells leading to growth 
factor expression that may promote survival of tumor cells (40). 
 
In the presence of physical activity, paradoxically, circulating IL-6 is markedly increased (41) 
and, at these levels, IL-6 can elicit anti-inflammatory effects due to its secretion from muscle 
(42). In our study, we believe that the elevated IL-6 levels are a marker of the positive effects of 
TCC on fat-free mass. At this point, we are unsure whether TCC-induced IL-6 is a mediator that 
contributes or a responder that reflects fat reduction, and whether it may have direct anti-
inflammatory effects on risk of recurrence. However, it is biologically plausible that TCC, which 
has both physical activity and meditative properties and can elicit similar positive effects on 
physical function as more traditional exercise programs, can dampen the pro-inflammatory state 
associated with cancer progression by increasing fat-free mass and reducing fat mass. Ultimately, 
we are interested in whether the association of IL-6 with lean body mass in breast cancer 
survivors produced by TCC could be a link between a healthy body weight and reduced risk of 
disease recurrence, a focus of future studies. We are also interested in whether the changes 
elicited by TCC are due to physical activity components, meditative components, or both. 
 
Similar patterns of associations for IL-2, fat-free mass, and fat mass were observed herein as 
were observed for IL-6, which may indicate another mechanism of physical activity-mediated 
changes that are beneficial for maintenance of a healthy body weight. IL-2 is produced by T cells 
as a necessary proliferative factor; these cells accumulate in adipose tissue (43) and likely play a 
role in the inflammatory response within this tissue (44) and may ultimately promote tumor 
progression. Physical activity, therefore, by increasing fat-free mass and reducing fat mass may 
lead to reduced adiposity, leading to reduced accumulation of T cells within adipose tissue and 
lower levels of IL-2, which may ultimately lower the likelihood of tumor progression. 
 
We found a positive correlation between changes in insulin and IFN-γ levels in the PST group; 
both insulin and IFN-γ increased in this group but remained relatively stable in the TCC group. 
Another study that assessed the effects of TCC on immune function found that TCC can enhance 
production of CD4+CD25+ regulatory T cells (45) which could mitigate IFN-γ production from 
inflammatory T cells in adipose tissue, thus providing another possible explanation for the 
difference in IFN-γ expression between groups. In a recent animal study of diet-induced obesity, 
IFN-γ promoted inflammation in adipose tissue and promoted insulin resistance (46), which 
provides a rationale for the positive correlation of IFN-γ and insulin observed in our non-
exercising group. Further studies are needed to determine whether the correlation of IFN-γ and 
insulin is causal. 
 
Based upon these preliminary data and the pertinent literature, we propose a model (Figure 1) 
whereby physically inactive breast cancer survivors will have a higher inflammatory status 
mediated by factors such as IL-2, IFN-γ, and TNF-α that are produced by T-cells, macrophages, 
and adipocytes. This inflammatory environment may directly enhance abnormal cellular 
proliferation which may increase weight gain and the risk of recurrence. Additionally, 
inflammation might promote insulin resistance and increased levels of insulin and IGFs in the 
blood that drive abnormal cellular proliferation and ultimately affect recurrence. We 
hypothesize, further, that the physical activity component of the TCC intervention could reduce 
the inflammatory state in breast cancer survivors through muscle release of IL-6, thus promoting 
anti-inflammatory processes and lowering insulin and IGF levels, which would maintain normal 
cellular proliferative processes, maintenance of a healthy body weight, and a reduced the rate of 
cancer recurrence. 
 
The major limitation of this study is small sample size; all conclusions from these data are 
preliminary. Even though we had a small sample size in this pilot study, we were able to detect a 
significant main effect of TCC on insulin levels. Higher powered confirmatory studies will allow 
for more precise determination of TCC-mediated effects on insulin and other biomarkers 
assessed in this study. Such studies should also assess the influence of menopausal status, pre-
morbid weight (e.g. obesity), other co-morbid conditions and medication usage on these markers. 
Also, we did not follow the study subjects for long enough to obtain adequate recurrence 
information for correlation with biological markers assessed. We did not use a criterion gold 
standard for body composition such as hydrostatic weighing or dual-energy x-ray 
absorptiometry; given the positive findings of this study, future studies should incorporate a gold 
standard. Additional studies should also include a measure of overall muscle strength. We were 
concerned about exercise contamination in this study; however, we previously reported that only 
20% of the PST group reported increasing their level of exercise, whereas 100% of the TCC 
group reported exercise due only to the intervention (34, 35). Future studies should include daily 
exercise diaries to more accurately reflect dose and intensity of any exercise. Lastly, our results 
pertain only to breast cancer survivors; studies of the effects of TCC in other cancer populations 
are needed. 
 
A major strength of this study is our preliminary identification of a significant difference in post-
intervention levels of insulin between TCC and PST groups; this difference suggests that the 
unique mind-body intervention, TCC, has a similar effect on insulin in breast cancer survivors as 
do traditional exercise regimens, making TCC a possible attractive alternative intervention. 
Furthermore, we identified novel relationships between cytokines, insulin, insulin-related 
molecules, and body composition that may explain the biological effects of our yang-style TCC 
intervention in breast cancer survivors. Future studies should investigate the relationships 
between these biological markers and recurrence rates in breast cancer survivors in a larger 
randomized controlled trial with a TCC intervention. 
 
CONCLUSION 
The results of this completed pilot study provide preliminary data suggesting that the integrative 
medicine intervention TCC can lower insulin levels in breast cancer survivors compared to a 
non-active control. We also found significant correlations between body composition and 
cytokines. While these significant findings are encouraging, given the small sample size, these 
analyses should be repeated in a larger study with higher power to be confirmatory. 
 
These results are very positive, and suggest that non-traditional exercise interventions with a 
mindfulness component, such as Tai Chi Chuan, may elicit similar beneficial effects to breast 
cancer survivors as more traditional exercise programs. Larger randomized studies are needed to 
assess the effects of Tai Chi Chuan on biomarkers that are likely related to weight gain and 
recurrence. Such a study could have a tremendous impact for breast cancer survivorship 
research. 
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